NBE Technologies, Merck KGaA, Darmstadt, Germany.
Discovery Biology, Syngene International, Bangalore, India.
MAbs. 2023 Jan-Dec;15(1):2251190. doi: 10.1080/19420862.2023.2251190.
Recently, there has been a co-evolution of mammalian libraries and diverse microfluidic approaches for therapeutic antibody hit discovery. Mammalian libraries enable the preservation of full immune repertoires, produce hit candidates in final format and facilitate broad combinatorial bispecific antibody screening, while several available microfluidic methodologies offer opportunities for rapid high-content screens. Here, we report proof-of-concept studies exploring the potential of combining microfluidic technologies with mammalian libraries for antibody discovery. First, antibody secretion, target co-expression and integration of appropriate reporter cell lines enabled the selection of acting agonistic bispecific antibodies. Second, a functional screen for internalization was established and comparison of autocrine versus co-encapsulation setups highlighted the advantages of an autocrine one cell approach. Third, synchronization of antibody-secreting cells prior to microfluidic screens reduced assay variability. Furthermore, a display to secretion switchable system was developed and applied for pre-enrichment of antibody clones with high manufacturability in conjunction with subsequent screening for functional properties. These case studies demonstrate the system's feasibility and may serve as basis for further development of integrated workflows combining manufacturability sorting and functional screens for the identification of optimal therapeutic antibody candidates.
最近,哺乳动物文库与各种用于治疗性抗体发现的微流控方法共同发展。哺乳动物文库能够保留完整的免疫库,以最终形式产生命中候选物,并促进广泛的组合双特异性抗体筛选,而几种现有的微流控方法为快速高通量筛选提供了机会。在这里,我们报告了概念验证研究,探索了将微流控技术与哺乳动物文库相结合进行抗体发现的潜力。首先,通过抗体分泌、目标共表达和适当报告细胞系的整合,实现了激动性双特异性抗体的选择。其次,建立了内化的功能筛选,并比较了自分泌与共包封设置,突出了自分泌单细胞方法的优势。第三,在微流控筛选之前对分泌细胞进行同步化,减少了测定变异性。此外,还开发了一种可从展示到分泌的切换系统,并将其应用于与随后的功能特性筛选相结合的高制造性抗体克隆的预富集。这些案例研究证明了该系统的可行性,并可能为进一步开发结合制造性分选和功能筛选的综合工作流程提供基础,以鉴定最佳的治疗性抗体候选物。